carbamates has been researched along with Colonic Neoplasms in 23 studies
Colonic Neoplasms: Tumors or cancer of the COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Encorafenib plus cetuximab with or without binimetinib showed increased objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared with chemotherapy plus anti-EGFR in previously treated patients with BRAF V600E-mutated (mut) metastatic colorectal cancer (mCRC)." | 9.51 | Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ( Antista, M; Antonuzzo, L; Bensi, M; Boccaccino, A; Borelli, B; Cremolini, C; Crespi, V; Giampieri, R; Giordano, M; Intini, R; Libertini, M; Lonardi, S; Moretto, R; Noto, C; Noto, L; Parisi, A; Passardi, A; Persano, M; Puccini, A; Rihawi, K; Rossini, D; Roviello, G; Salati, M; Tamberi, S; Zichi, C, 2022) |
| " In this article, the synthesis, characterization, and antiproliferative activity of four steroidal carbamates on mouse colon carcinoma CT26WT cells are described." | 8.12 | Synthesis of Four Steroidal Carbamates with Antitumor Activity against Mouse Colon Carcinoma CT26WT Cells: In Vitro and In Silico Evidence. ( Alonso, D; Brown Roldán, S; Castro, AZ; Ceballos, LG; Espinoza, L; García Díaz, M; García, YC; Olea, AF; Pacheco, DF; Piloto-Ferrer, J; Villa Testa, A; Wagner, SF, 2022) |
| "Encorafenib plus cetuximab with or without binimetinib showed increased objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared with chemotherapy plus anti-EGFR in previously treated patients with BRAF V600E-mutated (mut) metastatic colorectal cancer (mCRC)." | 5.51 | Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ( Antista, M; Antonuzzo, L; Bensi, M; Boccaccino, A; Borelli, B; Cremolini, C; Crespi, V; Giampieri, R; Giordano, M; Intini, R; Libertini, M; Lonardi, S; Moretto, R; Noto, C; Noto, L; Parisi, A; Passardi, A; Persano, M; Puccini, A; Rihawi, K; Rossini, D; Roviello, G; Salati, M; Tamberi, S; Zichi, C, 2022) |
| " In this article, the synthesis, characterization, and antiproliferative activity of four steroidal carbamates on mouse colon carcinoma CT26WT cells are described." | 4.12 | Synthesis of Four Steroidal Carbamates with Antitumor Activity against Mouse Colon Carcinoma CT26WT Cells: In Vitro and In Silico Evidence. ( Alonso, D; Brown Roldán, S; Castro, AZ; Ceballos, LG; Espinoza, L; García Díaz, M; García, YC; Olea, AF; Pacheco, DF; Piloto-Ferrer, J; Villa Testa, A; Wagner, SF, 2022) |
| "Encorafenib is a BRAF inhibitor increasingly used as a second-line treatment for metastatic melanoma and colorectal cancer." | 1.72 | Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases. ( Alfallouji, Y; Borysiewicz, C; Bunker, CB; Calonje, E; Hodgkinson, T; Perrett, CM; Sidwell, RU; Spencer, A; Wasan, H; Watchorn, R, 2022) |
| "Cardiovascular adverse events (CVAEs) associated with BRAF inhibitors alone versus combination BRAF/MEK inhibitors are not fully understood." | 1.62 | Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. ( Al-Kindi, S; Barnholtz-Sloan, JS; de Lima, M; Dowlati, A; Fradley, MG; Guha, A; Gutierrez, JM; Jain, C; Jain, P; Lenihan, D; Oliveira, GH, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (21.74) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 8 (34.78) | 2.80 |
| Authors | Studies |
|---|---|
| Omori, R | 1 |
| Miyagaki, T | 1 |
| Miyano, K | 1 |
| Hashimoto, Y | 1 |
| Kadono, T | 1 |
| Alfallouji, Y | 1 |
| Spencer, A | 1 |
| Calonje, E | 1 |
| Perrett, CM | 1 |
| Watchorn, R | 1 |
| Borysiewicz, C | 1 |
| Hodgkinson, T | 1 |
| Wasan, H | 1 |
| Bunker, CB | 1 |
| Sidwell, RU | 1 |
| Boccaccino, A | 1 |
| Borelli, B | 1 |
| Intini, R | 1 |
| Antista, M | 1 |
| Bensi, M | 1 |
| Rossini, D | 1 |
| Passardi, A | 1 |
| Tamberi, S | 1 |
| Giampieri, R | 1 |
| Antonuzzo, L | 1 |
| Noto, L | 1 |
| Roviello, G | 1 |
| Zichi, C | 1 |
| Salati, M | 1 |
| Puccini, A | 1 |
| Noto, C | 1 |
| Parisi, A | 1 |
| Rihawi, K | 1 |
| Persano, M | 1 |
| Crespi, V | 1 |
| Libertini, M | 1 |
| Giordano, M | 1 |
| Moretto, R | 1 |
| Lonardi, S | 1 |
| Cremolini, C | 1 |
| Pacheco, DF | 1 |
| Alonso, D | 1 |
| Ceballos, LG | 1 |
| Castro, AZ | 1 |
| Brown Roldán, S | 1 |
| García Díaz, M | 1 |
| Villa Testa, A | 1 |
| Wagner, SF | 1 |
| Piloto-Ferrer, J | 1 |
| García, YC | 1 |
| Olea, AF | 1 |
| Espinoza, L | 1 |
| Sancha, SAR | 1 |
| Szemerédi, N | 1 |
| Spengler, G | 1 |
| Ferreira, MU | 1 |
| Capdevila, J | 1 |
| Arqués, O | 1 |
| Hernández Mora, JR | 1 |
| Matito, J | 1 |
| Caratù, G | 1 |
| Mancuso, FM | 1 |
| Landolfi, S | 1 |
| Barriuso, J | 1 |
| Jimenez-Fonseca, P | 1 |
| Lopez Lopez, C | 1 |
| Garcia-Carbonero, R | 1 |
| Hernando, J | 1 |
| Matos, I | 1 |
| Paolo, N | 1 |
| Hernández-Losa, J | 1 |
| Esteller, M | 1 |
| Martínez-Cardús, A | 1 |
| Tabernero, J | 1 |
| Vivancos, A | 1 |
| Palmer, HG | 1 |
| Kim, YJ | 1 |
| Lee, DH | 1 |
| Choi, YS | 1 |
| Jeong, JH | 1 |
| Kwon, SH | 1 |
| Guha, A | 1 |
| Jain, P | 1 |
| Fradley, MG | 1 |
| Lenihan, D | 1 |
| Gutierrez, JM | 1 |
| Jain, C | 1 |
| de Lima, M | 1 |
| Barnholtz-Sloan, JS | 1 |
| Oliveira, GH | 1 |
| Dowlati, A | 1 |
| Al-Kindi, S | 1 |
| El-Khoury, R | 1 |
| Hafliger, E | 1 |
| Gallois, C | 1 |
| Louafi, S | 1 |
| Garinet, S | 1 |
| Zaanan, A | 1 |
| Taieb, J | 1 |
| Hayashi, R | 1 |
| Nakatsui, K | 1 |
| Sugiyama, D | 1 |
| Kitajima, T | 1 |
| Oohara, N | 1 |
| Sugiya, M | 1 |
| Osada, S | 1 |
| Kodama, H | 1 |
| Zhang, Z | 1 |
| Lau, J | 1 |
| Kuo, HT | 1 |
| Zhang, C | 1 |
| Hundal-Jabal, N | 1 |
| Colpo, N | 1 |
| Bénard, F | 1 |
| Lin, KS | 1 |
| Kawaratani, Y | 1 |
| Harada, T | 1 |
| Hirata, Y | 1 |
| Nagaoka, Y | 1 |
| Tanimura, S | 1 |
| Shibano, M | 1 |
| Taniguchi, M | 1 |
| Yasuda, M | 1 |
| Baba, K | 1 |
| Uesato, S | 1 |
| Doan Thi Mai, H | 1 |
| Gaslonde, T | 1 |
| Michel, S | 1 |
| Koch, M | 1 |
| Tillequin, F | 1 |
| Pfeiffer, B | 1 |
| Renard, P | 1 |
| Kraus-Berthier, L | 1 |
| Léonce, S | 1 |
| Pierré, A | 1 |
| Kohen, F | 1 |
| Gayer, B | 1 |
| Kulik, T | 1 |
| Frydman, V | 1 |
| Nevo, N | 1 |
| Katzburg, S | 1 |
| Limor, R | 1 |
| Sharon, O | 1 |
| Stern, N | 1 |
| Somjen, D | 1 |
| Garcia, P | 1 |
| Braguer, D | 1 |
| Carles, G | 1 |
| Briand, C | 1 |
| Kowalski, RJ | 1 |
| Giannakakou, P | 1 |
| Gunasekera, SP | 1 |
| Longley, RE | 1 |
| Day, BW | 1 |
| Hamel, E | 1 |
| Yao, X | 1 |
| Kwan, HY | 1 |
| Perloff, MD | 1 |
| von Moltke, LL | 1 |
| Fahey, JM | 1 |
| Daily, JP | 1 |
| Greenblatt, DJ | 1 |
| Weisburger, EK | 1 |
| Ulland, BM | 1 |
| Schueler, RL | 1 |
| Weisburger, JH | 1 |
| Harris, PN | 2 |
| Hu, JJ | 1 |
| Dimaira, MJ | 1 |
| Zirvi, KA | 1 |
| Dikdan, G | 1 |
| Lea, MA | 1 |
| Lalezari, I | 1 |
| Schwartz, EL | 1 |
| Ajani, JA | 1 |
| Hortobagyi, GN | 1 |
| Frye, D | 1 |
| Levin, B | 1 |
| Boman, BM | 1 |
| Faintuch, JS | 1 |
| Gibson, WR | 1 |
| Dillard, RD | 1 |
2 trials available for carbamates and Colonic Neoplasms
| Article | Year |
|---|---|
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colonic Neopl | 2022 |
A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma.
Topics: Antineoplastic Agents; Carbamates; Carcinoma; Clinical Trials as Topic; Colonic Neoplasms; Humans; P | 1987 |
21 other studies available for carbamates and Colonic Neoplasms
| Article | Year |
|---|---|
Multiple pigmented nevi induced by the combination of encorafenib and cetuximab in a colon cancer patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colonic Neoplasms; Colorectal | 2022 |
Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Exanthema; Humans; Mu | 2022 |
Synthesis of Four Steroidal Carbamates with Antitumor Activity against Mouse Colon Carcinoma CT26WT Cells: In Vitro and In Silico Evidence.
Topics: Animals; Antineoplastic Agents; Carbamates; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colonic | 2022 |
Lycorine Carbamate Derivatives for Reversing P-glycoprotein-Mediated Multidrug Resistance in Human Colon Adenocarcinoma Cells.
Topics: Adenocarcinoma; Amaryllidaceae Alkaloids; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2023 |
Epigenetic
Topics: Animals; Carbamates; Carcinoma, Neuroendocrine; Cetuximab; Colonic Neoplasms; Drug Resistance, Neopl | 2020 |
Benzo[
Topics: Carbamates; Cell Proliferation; Colonic Neoplasms; Enzyme Inhibitors; HeLa Cells; Histones; Humans; | 2019 |
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colonic Neoplasms; ErbB | 2021 |
Anti-tumor activities of Au(I) complexed with bisphosphines in HL-60 cells.
Topics: Apoptosis; Carbamates; Cell Proliferation; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fema | 2014 |
Synthesis and evaluation of (18)F-labeled 4-nitrobenzyl derivatives for imaging tumor hypoxia with positron emission tomography: Comparison of 2-[(18)F]fluoroethyl carbonate and 2-[(18)F]fluoroethyl carbamate.
Topics: Animals; Carbamates; Carbonates; Cell Line, Tumor; Colon; Colonic Neoplasms; Fluorine Radioisotopes; | 2016 |
New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group.
Topics: Acetates; Animals; Aspirin; Benzoates; Carbamates; Cell Division; Cell Line, Tumor; Colonic Neoplasm | 2011 |
Synthesis and cytotoxic and antitumor activity of 1,2-dihydroxy-1,2-dihydrobenzo[b]acronycine diacid hemiesters and carbamates.
Topics: Acronine; Animals; Antineoplastic Agents, Phytogenic; Carbamates; Cell Cycle; Colonic Neoplasms; Dru | 2004 |
Synthesis and evaluation of the antiproliferative activities of derivatives of carboxyalkyl isoflavones linked to N-t-Boc-hexylenediamine.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; Carbamates; Cell Line, T | 2007 |
[Effect of the association of antimitotic agents on cell lines of human adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Docet | 1994 |
The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
Topics: Alkanes; Animals; Antineoplastic Agents, Phytogenic; Binding, Competitive; Carbamates; Colonic Neopl | 1997 |
Activity of voltage-gated K+ channels is associated with cell proliferation and Ca2+ influx in carcinoma cells of colon cancer.
Topics: 4-Aminopyridine; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Carb | 1999 |
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line, Tran | 2000 |
Carcinogenicity of three dose levels of 1,4-Bis(4-fluorophenyl)-2-propynyl-N-cyclooctyl carbamate in male Sprague-Dawley and F344 rats.
Topics: Adenocarcinoma; Animals; Carbamates; Carcinogens; Colonic Neoplasms; Diet; Ear Neoplasms; Genotype; | 1975 |
Influence of pH on the modification of thiols by carbamoylating agents and effects on glutathione levels in normal and neoplastic cells.
Topics: Animals; Buthionine Sulfoximine; Carbamates; Colonic Neoplasms; Cyanates; DNA, Neoplasm; Glutathione | 1989 |
Synthesis and antineoplastic activity of 5-aryl-2,3-dihydropyrrolo[2,1-b]thiazole-6,7-dimethanol 6,7-bis(isopropylcarbamates).
Topics: Carbamates; Cell Division; Cell Survival; Chemical Phenomena; Chemistry; Colonic Neoplasms; Humans; | 1988 |
The oncogenicity of two 1,1-diaryl-2-propynyl N-cycloalkylcarbamates.
Topics: Adenocarcinoma; Alkynes; Animals; Carbamates; Colonic Neoplasms; Cycloparaffins; Lymphoma; Mammary N | 1970 |